Learn more As a plus-size woman, I know the struggle of finding great clothing in extended sizes. Fortunately, where once there were only two or three retailers catering to plus sizes, now there ...

ImmunoGen, Inc. has announced that its platinum-resistant ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) has been granted FDA accelerated approval. This first FDA antibody-drug ...

Below we've highlighted some notable scores on designer shoes, bags, and clothing from our favorite online luxury retailers — because everyone loves a good deal, whatever their budget may be.

More than 55% of patients taking Elahere, an ovarian cancer approved in 2022, may experience vision loss, according to a new study. The FDA's label for Elahere (mirvetuximab soravtansine ...

CHICAGO — A real-world study of the ocular side effects of the gynecological cancer treatment mirvetuximab (Elahere) has found more than two of three women taking the drug experienced some type ...

A continuation of strong growth trends is my baseline assumption for the two products. Addition of Elahere is driving the return to growth of the oncology portfolio For the oncology segment ...

Additionally, Ms. White helped to maximize the successful commercial launch of ELAHERE®, a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer. Before ...

Additionally, Ms. White helped to maximize the successful commercial launch of ELAHERE®, a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer. Before joining ...

Additionally, AbbVie's oncology segment benefited from solid sales of Venclexta and the newly acquired Elahere, reinforcing positive investor sentiment. For the current fiscal year, ending in ...

However, the strong sales performance of drugs like Rinvoq, Skyrizi, Venclexta and Vraylar, coupled with significant contributions from newer drugs Ubrelvy, Elahere, Epkinly and Qulipta ...

In the immortal words of the late, great entertainer Prince, forever "is a mighty long time." For investors, though 15 to 20 years can practically feel like forever. It can be hard to find stocks ...